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ABSTRACT
Objective: The purpose of the present study was to formulate and evaluate risperidone loaded bioflexi films for effective treatment of psychosis. For 
the preparation of bioflexi films, biopolymer was isolated from seeds of Euryale ferox (family Nymphaeaceae) by an economic method. The biopolymer 
recovered from the concentrate was subjected for various physiochemical properties such as color, solubility, color changing point, and chemical test.
Methods: The bioflexi films were prepared using this biopolymer, dextrose as flexicizer, and sween 80 as permeation enhancer in methanol and water 
as solvent system.
Results: The formulations were characterized including uniformity of weight, drug content, folding endurance, and thickness. To study the stability 
of the formulations and in vitro dissolution of the experimental formulations were performed to determine the amount of risperidone present in the 
patches and scanning electron microscopy of the prepared bioflexi films was taken to see the drug distribution pattern. Drug-excipient interaction 
studies were carried out using Fourier transform infrared spectroscopic technique. In vitro dissolution studies showed that the drug distribution 
in the bioflexi film was homogeneous and it was found that the maximum drug release in 24 h was 99.81% with formulation EF3. In vitro skin 
permeation study was also conducted in a modified Franz’s diffusion cell which shows that the maximum permeation with the formulation EF3 and 
it was 768.50 µg/cm2 after 24 h.
Conclusion: Optimized formulations were found to be suitable for formulating in terms of physicochemical characteristics and there was no significant 
interaction noticed between the drug and biopolymer used.
Keywords: Bioflexi film, Risperidone, Translabial, Euryale ferox.
INTRODUCTION
Translabial delivery constitutes one of the most important routes for 
new drug delivery system. Translabial delivery of drugs offers several 
advantages over conventional delivery including oral and injection 
methods. Translabial delivery, that traditionally uses a patch containing 
drug substances pressed onto the lip skin, is non-invasive, convenient, 
and painless, and can avoid gastrointestinal toxicity (e.g., ulcer diseases) 
and the hepatic first-pass metabolism [1].
Autism has been one of the major diseases affecting children’s in today 
scenario [2]. Risperidone, an antipsychotic drug, is supposed to be 
effective in treating behavioral disturbances in children with autism 
spectrum disorder (ASD). At present, risperidone is administered orally 
or by injection. It is usually administered as one or two daily oral dose, 
for an overall dosage of 4–16 mg/day [3].
The low-dose risperidone maintenance therapy is required to control 
the ASD in children’s and long-term prophylactic [13] treatment 
is needed to prevent relapses. Long-acting modified dosage forms 
of risperidone are going to be effective in patients and can help in 
addressing the problem of poor patient compliance [15]. The use of 
this drug in the lowest possible effective dosage is recommended for 
minimizing the risk of major side effects. Based on these hypotheses, 
a rate controlling bioflexi translabial drug delivery system was 
developed [16].
Simple drug-loaded rate controlling bioflexi film of translabial drug 
delivery system for risperidone was designed for prolonged period 
of maintenance therapy instead of conventional dosage form [14]. 
Moreover, the physicochemical characteristics of risperidone also 
comply with the general requirement for designing translabial drug 
delivery system to a good extent [4].
This study search and investigation are expected to add extensively 
to the existing knowledge and information in the field of proper drug 
regimen and maintenance therapy of ASD with rate controlling bioflexi 
films of risperidone. The major problem of transdermal drug delivery 
system is with the barrier properties of stratum corneum. Thus, 
the transport across the skin membrane is a complex phenomenon. 
Therefore, lip skin being the thinnest and richly supplied through 
blood vessels due to which our lips appear red in color could serve as 
a novel route for drug delivery. The translabial application of drugs 
provides several benefits including the avoidance of hepatic first-pass 
metabolism and ability to provide nearly constant drug delivery over 
a long period which may reduce systemic adverse effects. Moreover, 
mucoadhesion studies were also conducted in an effort to understand 
drug distribution in the patches and the permeation of drug through 
skin [5].
METHODS
Risperidone was received as a gift sample from Neuro Lifecare, Baddi, 
Himachal Pradesh. All other chemicals used in the study were of 
analytical grade.
Development of bioflexi films
A polymeric solution (3% w/v) was prepared by dissolving Euryale 
ferox with risperidone (20% w/w of dry weight of polymer), 
dextrose as a plasticizer, and sween-80 as a permeation enhancer in 
methanol:water (1:1) as a solvent system.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i6.31280
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Table 1: Composition of bioflexi films
Ingredient EF1 EF2 EF3 EF4 EF5 EF6 EF7 HPMC
Risperidone (mg) 20 20 20 20 20 20 20 20
Euryale Ferox (biopolymer) (mg) 100 200 300 400 500 600 700 200
Dextrose (mg) 80 80 80 80 80 80 80 80
Glycerine (mL) 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
Sween 80 (mL) 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
Double distilled water (mL) 20 20 20 20 20 20 20 20
HPMC: Hydroxy propyl methyl cellulose, EF: Euryale ferox 
Fig. 1: Scanning electron microscopy image showing risperidone 
drug particle in bioflexi film
Fig. 2: Scanning electron microscopy image showing bioflexi film 
after release
First, the solution was prepared with different ratios of polymeric blend 
without adding sween-80 as a permeation enhancer. The composition 
of prepared bioflexi film is given in Table 1. Then again, the films were 
developed using the procedure mentioned above on adding one drop 
of sween-80 and stirred for 45 min on magnetic stirrer to accomplish 
homogeneous mixture. After mixing the drug and polymer, solution was 
allowed to stand for 15 min to remove air bubbles and the solution is 
poured in the Petri dish. The solvent was allowed to evaporate at 40°C 
for 24 h to achieve drug-polymer bioflexi film. After 24 h, the film was 
collected and stored in desiccators until further use.
Evaluation of bioflexi films
Uniformity of weight
Ten different films from individual batches were weighed individually 
and the average weight was calculated; the individual weight should not 
deviate significantly from the average weight [6].
Drug content determination
An accurately weighed portion of film was dissolved in 100 mL of 
methanol in which drug is soluble and then the solution was shaken 
continuously for 24 h in a mechanical shaker. Then, the whole solution 
was sonicated. After sonication, drug in solution was estimated 
spectrophotometrically by dilution [7].
Folding endurance
The film was cut evenly and repeatedly folded at same place till it broke. 
The number of times the film could be folded at the same place without 
breaking gave the value of folding endurance [8].
Thickness of the film
The thickness of the drug-loaded film was measured at five different 
points using Vernier caliper. The average and standard deviation of five 
readings were calculated for each batch of drug-loaded films [9].
In vitro release studies
It is needed to maintain greater drug concentrations at the lip skin than 
in the body. This is required to achieve a constant rate of permeation. 
The permeation study using Franz diffusion cell with a capacity of 35 mL 
carried out at 32°C ± 0.5°C. A section of film was cut and placed in donor 
compartment keeping backing membrane on the upper side. This whole 
assembly was kept on a magnetic stirrer and the solution was stirred 
continuously using a magnetic bead. Phosphate saline buffer of pH 7.4 
with 0.5% sween-80 was used as a media for permeation studies. 
A similar set was run simultaneously without using the film at the donor 
compartment egg membrane as a control. The samples were withdrawn 
at different time intervals and replaced with equal amount of dissolution 
media and then analyzed using a UV spectrophotometer at 322 nm [10].
In vitro permeation studies
The in vitro permeation studies were carried out in a Franz diffusion cell 
with a capacity of 35 mL, using eggshell membrane. A section of eggshell 
membrane was cut and placed in the donor compartment, and the film 
was placed on the membrane. The holder, containing the egg membrane 
and the formulation, was placed on the receiver compartment of the 
cell containing phosphate saline buffer of pH 7.4 with 0.5% sween-80. 
The temperature of the cell was maintained at 32°C ± 5°C by circulating 
water jacket. This whole assembly was kept on a magnetic stirrer and the 
solution was stirred continuously using a magnetic bead. A similar set was 
run simultaneously without using the patch at the donor compartment as 
a skin control. The samples were withdrawn at different time intervals and 
replaced with equal amount of dissolution media. Samples were analyzed 
spectrophotometrically at 322 nm and the amount of drug permeated per 
cm2 of patch was calculated from the standard curve and plotted against 
time. The difference between the readings of drug skin permeation and 
skin control was used as the actual reading in each case [11].
Scanning electron microscopy
The morphology of the bioflexi film was analyzed using a scanning 
electron microscope. The section of the film was cut and mounted on 
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stubs using an adhesive tape Figs. 1 and 2. The samples placed on the 
stubs were coated with gold-palladium alloy using a fine coat ion sputter 
(JOEL, Fine Coat Ion Sputter JFC-1100). The sections were examined 
under scanning electron microscope (JSM 6100 JEOL, Tokyo, Japan) [12].
Fig. 3: Drug content of prepared bioflexi films using a different ratio of Euryale ferox mean (n = 3) ± standard deviation
Fig. 4: Folding endurance of prepared bioflexi films using a different ratio of Euryale ferox mean (n = 3) ± standard deviation
Fig. 5: Thickness of prepared bioflexi films using a different ratio of Euryale ferox mean (n = 3) ± standard deviation
Table 2: Evaluation of transdermal patch for uniformity of weight (mg), drug content, flatness, folding endurance, and thickness (mm)
Formulation code Uniformity of weight Drug content (%) Flatness (%) Folding endurance Thickness
EF1 160±0.816 73.90±2.619 100 117.67±1.247 0.32±0.025
EF2 172±1.632 89.65±2.043 100 130.67±0.942 0.41±0.020
EF3 179.67±1.249 88.67±0.845 100 153.67±2.054 0.52±0.026
EF4 190.33±2.054 97.35±0.830 100 184±1.632 0.67±0.033
EF5 196.67±1.247 70.85±0.455 100 191±2.160 0.87±0.021
EF6 207.33±2.054 64.76±6.033 100 208.33±6.236 1.03±0.074
EF7 215±2.449 72.41±1.683 100 183.33±5.436 1.08±0.066
HPMC 176±2.160 90.71±0.490 100 81.33±1.247 0.41±0.005
HPMC: Hydroxy propyl methyl cellulose, EF: Euryale ferox
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RESULTS AND DISCUSSION
A total of 35 formulations were prepared using E. ferox and HPMC 
polymers as per given formula in Table 1. All the films were evaluated 
for their physicochemical parameters, and they were found to be 
transparent, smooth, and flexible. They were also found to be uniform 
in their weight and thickness with low SD values, as shown in Table 2 
and Figs. 3-5. A transdermal patch should possess a smooth surface and 
should not constrict with time. No constriction was observed in any of 
the prepared formulations; all the surfaces were 100% flat (Table 2). 
Fourier transform infrared was carried out to check the interaction 
between the drug Fig. 6 and excipients Fig. 7. Graphs of drug and drug 
excipients confirmed that there is no interaction between the drug and 
excipients used Fig. 8.
In vitro release and permeation studies
Drug release from polymer matrix and drug dissolution ensured 
sustained reproducibility of rate and duration of drug release. 
Dissolution studies for different formulations were carried out 
using modified USP paddle-type apparatus using PBS 7.4 with 0.5% 
tween 80 as dissolution fluid at 32°C ± 0.5°C. The in vitro studies 
of the formulations (EF1 to EF7) and the standard polymer HPMC 
were shown. All the formulations released >90% of drug within 10 h. 
Formulation EF3 showed the maximum release of 99.81% at the 
end of 24 h [Figs. 9,10]. Formulation EF5 showed the slowest drug 
release and showed maximum drug release of 95.6% after 24 h. We 
could not detect any relationship between the drug release profile 
and the polymer composition. We can only conclude that the release 
mechanism might include diffusion as well as erosion since the 
biopolymer isolated is slightly soluble in water. The release data of 
tested strips were analyzed on the basis of the Korsmeyer–Peppas 
equation and Higuchi kinetics (by BIT-SOFT 1.12: drug release 
kinetics with model fitting). Coefficients of correlation (R2) were 
used to evaluate the accuracy of fit. The R2 values for the Higuchi 
and Peppas kinetic models were calculated and compared. All the 
tested formulations gave good fit to the Korsmeyer–Peppas model. 
All formulations showed non-Fickian drug release (0.5<n<1). On 
the basis of above determinations, EF3 was selected as the best 
formulations.
In vitro permeation study is predictive of an in vivo performance of 
drug. This study was carried out using different formulations in a Franz 
diffusion cell using eggshell membrane. This study helps in confirmation 
of better permeation of drug through skin. Mean cumulative amounts of 
drug released per cm2 of patch after 24 h were found to be 150.5, 389.9, 
768.5, 512.2, 448.2, 309.1, 218.3, and 734.2 µg/cm2 [Fig. 11].
Fig. 6: Infrared spectra of drug risperidone
Fig. 7: Infrared spectra of Euryale ferox biopolymer
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Fig. 8: Infrared spectra of drug, Euryale ferox
CONCLUSION
Flexible, smooth, and transparent films were obtained. It was found 
that the bioflexi films EF3 showed best release and permeation. 
Again, it was concluded here that the formulation EF3 showed 
better permeability among the prepared bioflexi films for 
risperidone. Bioadhesive bio-lipstrip based on E. ferox biopolymer 
was developed and shown to release drug over the required 
period of time (12 h). Thus, a stable bio-lipstrip of risperidone 
for the treatment of psychosis using this novel biopolymer was 
demonstrated. The biopolymer showed good film-forming ability. 
Thus, this natural biopolymer could be promising excipient for the 
systemic delivery of drugs through labial route or other translabial 
routes.
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